Published in Cancer Weekly, August 29th, 2006
According to recent research published in the journal Cancer Chemotherapy and Pharmacology, "The safety and efficacy of a combined regimen of weekly paclitaxel and gemcitabine was tested in patients with refractory and sensitive small-cell lung cancer (SCLC). Treatment consisted of paclitaxel 80 mg/m2 on days 1, 8, 15 and gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks. Of the 31 patients enrolled, 10 had refractory and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.